MSB 0.89% $1.14 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-113

  1. 218 Posts.
    lightbulb Created with Sketch. 12
    You can believe if its not a randomized trial and solely their drug being tested??
    Someone tell me I'm wrong...
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.